Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCeiba Investme. Regulatory News (CBA)

Share Price Information for Ceiba Investme. (CBA)

Share Price is delayed by 15 minutes
Get Live Data
29.00    0.00 (0.00%)
Bid:
24.00
Ask:
34.00
Spread: 10.00 (41.667%)
Market Cap: £47.91m
CBA Live PriceLast checked at - London Stock Exchange

Intraday Ceiba Investme. Share Chart

Trading Statement

3 Jun 2019 12:59

RNS Number : 9633A
Ceiba Investments Limited
03 June 2019
Β 

Β 

3 June 2019

CEIBA INVESTMENTS LIMITED

(TICKER CBA, ISIN: GG00BFMDJH11)

TRADING UPDATE

Β 

CEIBA Investments Limited ("CEIBA" or the "Company"), the largest listed foreign investor solely dedicated to investing in Cuba, is pleased to provide the following update on trading.

Q1 2019 Results

As announced on 29 May 2019, the Company's unaudited IFRS net asset value per share ("NAV") as at 31 March 2019 was US$1.5073 (31 December 2018 audited NAV: US$1.4937). This increase reflects US$1.9 millionΒ of net comprehensive income recognised during the quarter. This was principally attributable to US$3.4 million of dividend income received by the Company, net of non-controlling interests, from its equity investments in Cuban joint venture companies.

However, as a result of the strengthening of the British Pound during this period (GBP:US$ FOREX as at 31 March 2019 of 1.3053 compared to 1.2691 as at 31 December 2018), the unaudited IFRS NAV expressed in Sterling at 31 March 2019 was lower, at Β£1.1547, than as at 31 December 2018, Β£1.1770.

The non-IFRS unaudited NAV as at 31 March 2019 was US$1.5406 (31 December 2018: US$1.5288) or Β£1.1802 (31 December 2018: Β£1.2046). These figures include an adjustment recognising the full amount of US$5.0 million (Β£3.9 million) received from Aberdeen Standard Fund Managers Limited in connection with the execution of the Management Agreement (rather than deferring this amount over the five-year term of the Management Agreement as required by IFRS).

Strengthening of the US Cuban Embargo

The recent steps taken by the Trump administration to further strengthen the US Cuban Embargo, which has included limiting remittances, further restricting travel by US persons to Cuba and allowing Title III of the extraterritorial Helms-Burton Act to come into force, have resulted in a decline in US travel to the island and are expected to have a negative impact on the Cuban economy. In light of these aggressive steps, the Company is highly encouraged that Cuba continues to allow the timely transfer of hard currency to the foreign shareholders of the Cuban joint ventures in which the Company participates. The Company is also grateful for the immediate support provided by the European Union and various other countries in publicly repeating their long-standing determination that the application of Title III of the Helms-Burton Act is contrary to international law and confirming support for the companies under their jurisdiction having legitimate investments in Cuba.

The Spanish Cuban Debt Conversion Programme ("the Programme")

In April 2019, the Company announced that two Cuban joint venture companies in which CEIBA participates were awarded an aggregate amount of US$18.25 million under the Spanish Cuban Debt Conversion Programme.Β TosCuba S.A. (in which CEIBA has an economic interest of 40%) was awarded US$10 million in connection with the construction of the MeliΓ£ Trinidad Playa Hotel near Trinidad, Cuba, and Miramar S.A. (in which CEIBA has a 32.5% economic interest) was awarded US$8.25 million in connection with the MeliΓ£ Habana expansion project.

Under these awards, local currency invoices relating to services and materials received in Cuba in the course of the construction of the projects will be paid on behalf of the Cuban joint venture companies from Programme funds, thereby reducing the financing that CEIBA may have otherwise needed to provide. There is no obligation to reimburse funds awarded under the Programme.

In May 2019, TosCuba S.A. received the first US$2.5 million tranche of its award from the Programme.

Amended FINTUR Facility

On 31 May 2019, the Company amended its existing syndicated €24 million secured loan facility in favour of the Cuban finance company Casa Financiera FINTUR S.A. ("FINTUR") in order to extend to FINTUR a second tranche in the principal amount of €12 million, which will be repaid in instalments over 2 years. The Company's participation in this new tranche is €2 million.Β 

The Company has provided loan facilities to FINTUR since 2001 for a total aggregate amount of €140 million, which have been repaid in full without default.Β 

Β 

John Herring, Chairman of CEIBA Investments Limited, said:

Β 

"We are pleased by the Q1 results of the Company and the continuing progress being made with respect to our investment programmes. We are confident, notwithstanding the adverse recent steps taken by the US administration towards Cuba, that CEIBA's growing investment programmes will prove to be mutually beneficial to the Company and to the Cuban economy, Cuba and its people."

Β 

Β 

For further information, please contact:

Β 

Aberdeen Standard Fund Managers Limited

Sebastiaan Berger / Gary Jones / Christian Pittard

Β 

Tel: +44 (0)20 7463 6000

N+1 Singer

James Maxwell / James Moat (Corporate Finance)

James Waterlow (Sales)

Β 

Tel: +44 (0)20 7496 3000

Β 

Β 

Β 

END

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
TSTKMGGVMFKGLZM
12
Date   Source Headline
5th Jun 20268:33 amRNSTrading Update
27th May 20263:39 pmRNSHolding(s) in Company
22nd May 20262:30 pmRNSHolding(s) in Company
20th May 20263:37 pmRNSHolding(s) in Company
19th May 20261:07 pmRNSHolding(s) in Company
15th May 202612:40 pmRNSDirector/PDMR Shareholding
12th May 20267:00 amRNSIssue of Equity
30th Apr 20267:00 amRNSAnnual Financial Report
14th Apr 20264:46 pmRNSResult of EGM
1st Apr 202611:21 amRNSFurther re Second Amendment of Bond Instrument
27th Feb 20265:14 pmRNSFurther re Second Amendment of Bond Instrument
27th Feb 20262:26 pmRNSDirectorate change
13th Feb 20265:13 pmRNSStatement re Second Amendment of Bond Instrument
13th Feb 20263:20 pmRNSDirector Declaration
12th Feb 20265:32 pmRNSChange of Auditor
5th Feb 20267:00 amRNSTrading Update - Consultation with Bondholders
26th Jan 20263:36 pmRNSDirector/PDMR Shareholding
23rd Dec 20251:39 pmRNSNet Asset Value(s)
4th Dec 20253:25 pmRNSAppointment of Senior Independent Director
2nd Oct 20252:48 pmRNSDirector/PDMR Shareholding
29th Sep 20257:00 amRNSHalf-year Report
12th Sep 20253:16 pmRNSDirectorate Change
8th Jul 20257:00 amRNSTrading Update - Payment to Bondholders
4th Jul 202512:49 pmRNSDirectorate Change
3rd Jul 20253:14 pmRNSResult of AGM
1st Jul 20251:35 pmRNSNet Asset Value(s)
30th Apr 20257:00 amRNSAnnual Financial Report
28th Apr 202510:26 amRNSDirectorate Change
3rd Feb 20257:00 amRNSStatement re Amendment of Bond Instrument
13th Jan 20255:51 pmRNSStatement re Amendment of Bond Instrument
11th Dec 20241:31 pmRNSNet Asset Value(s)
7th Oct 202410:55 amRNSDirector/PDMR Shareholding
7th Oct 20247:00 amRNSStatement re Update from the Chairman
27th Sep 20247:00 amRNSHalf-year Report to 30 June 2024
13th Aug 20248:36 amRNSDirectorate Change
20th Jun 20243:09 pmRNSDirector/PDMR Shareholding
20th Jun 20247:00 amRNSNet Asset Value(s)
18th Jun 20244:53 pmRNSResult of AGM
30th Apr 20247:00 amRNSAnnual Financial Report
25th Mar 202411:03 amRNSDirectorate Change
17th Jan 20247:00 amRNSInvestment Update
27th Dec 20239:17 amRNSNet Asset Value(s)
18th Dec 20238:54 amRNSDirector/PDMR Shareholding
3rd Nov 202310:36 amRNSHolding(s) in Company
1st Nov 20239:05 amRNSDirector/PDMR Shareholding
27th Oct 202311:11 amRNSDirector/PDMR Shareholding
16th Oct 20238:37 amRNSAppointment of Non-Executive Director
12th Oct 20234:26 pmRNSDirector/PDMR Shareholding
5th Oct 202310:24 amRNSDirector/PDMR Shareholding
29th Sep 20237:00 amRNSHalf-year Report
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.